Reimbursement Review Reports
( Last Updated : July 26, 2021)
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | Feb 14, 2014 | Sep 23, 2014 |
| Adcetris | Brentuximab Vedotin | Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) | Reimburse with clinical criteria and/or conditions | Complete | Apr 2, 2020 | Dec 3, 2020 |
| Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | Mar 15, 2013 | Dec 5, 2013 |
| Adcetris | Brentuximab Vedotin | HL at high risk of relapse or progression post-ASCT | Reimburse with clinical criteria and/or conditions | Complete | Aug 10, 2017 | Feb 21, 2018 |
| Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Reimburse with clinical criteria and/or conditions | Complete | Mar 30, 2020 | Dec 3, 2020 |
| Adcetris | Brentuximab vedotin | Withdrawn | Apr 5, 2016 | |||
| Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Reimburse | Complete | Oct 8, 2019 | Jun 4, 2020 |
| Adcetris | Brentuximab vedotin | Hodgkin Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | Mar 14, 2013 | Aug 29, 2013 |
| Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | Aug 27, 2018 | Mar 7, 2019 |
| Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | Feb 27, 2012 | Aug 30, 2012 |